Patent intelligence · US
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
Patent details — US 11878053
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 23, 2024
- Expiration
- Jan 18, 2044
- Applicant
- IO Biotech ApS
- Claims
- 6
- CPC classes
- A61K, A61K2039/53, A61K2039/545, A61K2039/55522
Quick answer
US 11878053 (Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof) is held by IO Biotech ApS. Status: granted. Granted Jan 23, 2024. Expires Jan 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IO Biotech ApS
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K2039/53, A61K2039/545, A61K2039/55522, A61K2039/55527, A61K2039/55533
More from IO Biotech ApS
Related pharmaceutical patents in our USPTO index.
-
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12215135
PDL2 compounds
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 12077785
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
granted -
US 11981944
Immunogenic arginase peptides
granted
Frequently asked questions
What is US patent 11878053?
US 11878053 (Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof) is held by IO Biotech ApS. Status: granted. Granted Jan 23, 2024. Expires Jan 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11878053?
IO Biotech ApS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 11878053 expire?
Our index shows an expiration date of Jan 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.